A New Intestinal Model for Analysis of Drug Absorption and Interactions Considering Physiological Translocation of Contents

被引:4
作者
Asano, Satoshi [1 ,2 ]
Yoshitomo, Aoi [1 ]
Hozuki, Shizuka [1 ]
Sato, Hiromi [1 ]
Kazuki, Yasuhiro [3 ,4 ]
Hisaka, Akihiro [1 ]
机构
[1] Chiba Univ, Grad Sch Pharmaceut Sci, Clin Pharmacol & Pharmacometr, Chiba, Japan
[2] Teijin Pharma Ltd, DMPK Res Dept, Tokyo, Japan
[3] Tottori Univ, Chromosome Engn Res Ctr, Tottori, Japan
[4] Tottori Univ, Div Genome & Cellular Funct, Dept Mol & Cellular Biol, Sch Life Sci,Fac Med, Tottori, Japan
关键词
SEGREGATED-FLOW MODEL; COMPARTMENTAL ABSORPTION; GASTROINTESTINAL TRANSIT; HEPATIC ELIMINATION; 1ST-PASS METABOLISM; DISPERSION MODEL; SUBSTRATE DRUGS; RISK-ASSESSMENT; BLOOD-FLOW; PREDICTION;
D O I
10.1124/dmd.121.000361
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Precise prediction of drug absorption is key to the success of new drug development and efficacious pharmacotherapy. In this study, we developed a new absorption model, the advanced translocation model (ATOM), by extending our previous model, the translocation model. ATOM reproduces the translocation of a substance in the intestinal lumen using a partial differential equation with variable dispersion and convection terms to describe natural flow and micromixing within the intestine under not only fasted but also fed conditions. In comparison with ATOM, it was suggested that a conventional absorption model, advanced compartmental absorption and transit model, tends to underestimate micromixing in the upper intestine, and it is difficult to adequately describe movements under the fasted and fed conditions. ATOM explains the observed nonlinear absorption of midazolamsuccessfully, with a minimal number of scaling factors. Furthermore, ATOM considers the apical and basolateral membrane permeabilities of enterocytes separately and assumes compartmentation of the lamina propria, including blood vessels, to consider intestinal blood flow appropriately. ATOM estimates changes in the intestinal availability caused by drug interaction associated with inhibition of CYP3A and P-glycoprotein in the intestine. Additionally, ATOM can estimate the drug absorption in the fed state considering delayed intestinal drug flow. Therefore, ATOM is a useful tool for the analysis of local pharmacokinetics in the gastrointestinal tract, especially for the estimation of nonlinear drug absorption, which may involve various interactions with intestinal contents or other drugs. SIGNIFICANCE STATEMENT The newly developed advanced translocation model precisely explains various movements of intestinal contents under fasted and fed conditions, which cannot be adequately described by the current physiological pharmacokinetic models.
引用
收藏
页码:581 / 591
页数:11
相关论文
共 52 条
  • [1] Predicting the impact of physiological and biochemical processes on oral drug bioavailability
    Agoram, B
    Woltosz, WS
    Bolger, MB
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2001, 50 : S41 - S67
  • [2] Determinants of Intestinal Availability for P-glycoprotein Substrate Drugs Estimated by Extensive Simulation With Mathematical Absorption Models
    Ando, Hirotaka
    Hatakeyama, Hiroto
    Sato, Hiromi
    Hisaka, Akihiro
    Suzuki, Hiroshi
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (09) : 2771 - 2779
  • [3] A New Physiologically Based Pharmacokinetic Model for the Prediction of Gastrointestinal Drug Absorption: Translocation Model
    Ando, Hirotaka
    Hisaka, Akihiro
    Suzuki, Hiroshi
    [J]. DRUG METABOLISM AND DISPOSITION, 2015, 43 (04) : 590 - 602
  • [4] Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria
    Bentz, Joe
    O'Connor, Michael P.
    Bednarczyk, Dallas
    Coleman, JoAnn
    Lee, Caroline
    Palm, Johan
    Pak, Y. Anne
    Perloff, Elke S.
    Reyner, Eric
    Balimane, Praveen
    Brannstrom, Marie
    Chu, Xiaoyan
    Funk, Christoph
    Guo, Ailan
    Hanna, Imad
    Heredi-Szabo, Krisztina
    Hillgren, Kate
    Li, Libin
    Hollnack-Pusch, Evelyn
    Jamei, Masoud
    Lin, Xuena
    Mason, Andrew K.
    Neuhoff, Sibylle
    Patel, Aarti
    Podila, Lalitha
    Plise, Emile
    Rajaraman, Ganesh
    Salphati, Laurent
    Sands, Eric
    Taub, Mitchell E.
    Taur, Jan-Shiang
    Weitz, Dietmar
    Wortelboer, Heleen M.
    Xia, Cindy Q.
    Xiao, Guangqing
    Yabut, Jocelyn
    Yamagata, Tetsuo
    Zhang, Lei
    Ellens, Harma
    [J]. DRUG METABOLISM AND DISPOSITION, 2013, 41 (07) : 1347 - 1366
  • [5] Simulations of the Nonlinear Dose Dependence for Substrates of Influx and Efflux Transporters in the Human Intestine
    Bolger, Michael B.
    Lukacova, Viera
    Woltosz, Walter S.
    [J]. AAPS JOURNAL, 2009, 11 (02): : 353 - 363
  • [6] INFLUENCE OF FOOD ON MIDAZOLAM ABSORPTION
    BORNEMANN, LD
    CREWS, T
    CHEN, SS
    TWARDAK, S
    PATEL, IH
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (01) : 55 - 59
  • [7] Chen JP, 1997, J PHARMACOL EXP THER, V280, P24
  • [8] Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model
    Chen, Yuan
    Cabalu, Tamara D.
    Callegari, Ernesto
    Einolf, Heidi
    Liu, Lichuan
    Parrott, Neil
    Peters, Sheila Annie
    Schuck, Edgar
    Sharma, Pradeep
    Tracey, Helen
    Upreti, Vijay V.
    Zheng, Ming
    Zhu, Andy Z. X.
    Hall, Stephen D.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (09): : 685 - 695
  • [9] Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition
    Chu, Xiaoyan
    Galetin, Aleksandra
    Zamek-Gliszczynski, Maciej J.
    Zhang, Lei
    Tweedie, Donald J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (05) : 788 - 792
  • [10] Cong D, 2000, DRUG METAB DISPOS, V28, P224